

대한소화기암연구학회

**제37회 학술집담회 및  
하계 연구 심포지엄**

**A case of complete remission after  
palliative chemotherapy for  
pancreatic cancer**

**Jae Jin Lee**, Han Taek Jeong, and Ji min Han  
Department of Internal Medicine, Daegu Catholic  
University School of Medicine  
Email: sunrise127@naver.com

## I Female, 61 years old

### Chief complaint

Indigestion for 1 month

### Present illness

2022.02.03 Outside hospital

Indigestion, Weight loss 2kg for 1 month

USG/CT (22.02.15) → Pancreatic head cancer, 1.8cm

2022.2.17 DCUMC

EUS-FNB (22.02.21) → Cytology: adenocarcinoma, suggestive of

CA 19-9 3965, CEA 38.2

## I Female, 61 years old

### **Past Medical history**

HTN / Dyslipidemia / Hepatitis/ Tb: (+/+/-/-)

**Family history:** none


**Operation history:** none

### **Social history**

Smoking: none

Alcohol: none

# I Outside hospital CT (2022.02.15)



## I Initial lab findings (2022.02.20)

CBC:  $7,100/\mu l$  –  $13.1g/dl$  –  $283000/\mu l$

PT/aPTT: 11.7sec / 23.6 sec

AST/ALT: 15 U/L / 12 U/L, ALP: 117 U/L

T-bil: 0.5 mg/dL, D-bil: <0.2 mg/dL

Amylase/Lipase: 49 U/L / 29 U/L

BUN/Cr: 8.9 mg/dL / 0.6 mg/dL


CA 19-9 : **3965** U/mL

CEA: **38.2** ng/mL





# I EUS-FNB (2022.02.21)





EUS-FNB needle : 25 gauge, 5 passes



# I PET CT (2022.03.02)



# I Pancreas MRI (2022.03.02)





## I Clinical course - 1

### Final diagnosis

Pancreatic cancer, cT4N1M1, stage IV

### Plan

Palliative chemotherapy

ECOG PS : 0


1<sup>st</sup> line : FOLFIRINOX

## I Clinical course - 1

FOLFIRINOX L1C1D1=22.03.03

FOLFIRINOX L1C3D1=22.04.01 (75% Dose reduction d/t neutropenia and peripheral neuropathy)

FOLFIRINOX (75%) L1C5D1=22.04.29 (PR)



Mass size 2.6 cm → 1.5cm

Metastatic nodule size decreased  
(Liver S6)

Lymph node size decreased  
(Portocaval)

CA 19-9/CEA 595 U/mL / 4.82 ng/mL


## I Clinical course - 1

FOLFIRINOX L1C1D1=22.03.03

FOLFIRINOX L1C3D1=22.04.01 (75% Dose reduction d/t neutropenia and peripheral neuropathy)

FOLFIRINOX (75%) L1C5D1=22.04.29 (PR)

FOLFIRINOX (75%) L1C9D1=22.06.23 (PR)



Mass size 1.5 cm → 1.1cm

Metastatic nodule disappeared  
(Liver S6)

Lymph node size decreased  
(Portocaval)

CA 19-9/CEA 26 U/mL / 2.44 ng/mL

## I Clinical course - 1


FOLFIRINOX L1C1D1=22.03.03

FOLFIRINOX L1C3D1=22.04.01 (75% Dose reduction d/t neutropenia and peripheral neuropathy)

FOLFIRINOX (75%) L1C5D1=22.04.29 (PR)

FOLFIRINOX (75%) L1C9D1=22.06.23 (PR)

FOLFIRINOX (75%) L1C17D1=22.10.20 (CR)



No visible mass

CA 19-9/CEA 23 U/mL / 2.76 ng/mL

## I Clinical course - 2

### **Chemotherapy**

FOLFIRINOX (75%) L1C24D1 = 2023.01.26

### **Pre-OP evaluation**

PET CT (23.02.27)


Almost disappeared hypermetabolic lesions in pancreatic head, peripancreatic lymph node and right lobe of liver

No evidence of abnormal hypermetabolic lesion, suggesting distant metastasis

Liver MRI (23.02.27)

Markedly decreased p-head cancer and Hepatic metastasis in S6.

## Pylorus preserving pancreaticoduodenectomy (23.03.27)



Atypical gland, but no evidence of residual tumor

### Adjuvant chemotherapy

Gemcitabine C1D1 = 2023.05.10

Gemcitabine C1D8 = 2023.05.17

# I Summary

Pancreatic cancer, cT4N1M1, stage IV

Palliative chemotherapy

FOLFIRINOX L1C1~C2 (22.03.03~03.17)

75% FOLFIRINOX L1C3~C24 (22.04.01~23.01.26)

BPCT(23.02.08)

No visible primary tumor of pancreatic head

PET CT, MRI(23.02.27)

No metastasis

PPPD (23.03.27)

Tumor regression grade : Near total regression

Postoperative staging: pT1aN0M0, stage IA

Adjuvant chemotherapy

Gemcitabine C1D1 on 2023.05.10, C1D8 on 2023.05.17



DCMC 대구가톨릭대학교의료원

Thank you for your attention